OverviewSuggest Edit

Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
TypePublic
Founded2006
HQEmeryville, US
Websitezogenix.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2019)141(+57%)
Job Openings30
Revenue (FY, 2019)$3.6 M
Share Price (Sept 2020)$17.5 (-1%)
Cybersecurity ratingAMore

Key People/Management at Zogenix

Stephen J. Farr

Stephen J. Farr

President and Chief Executive Officer, Director
Gail M. Farfel

Gail M. Farfel

Executive Vice President and Chief Development Officer
Bradley S. Galer

Bradley S. Galer

Executive Vice President and Chief Medical Officer
Ashish Sagrolikar

Ashish Sagrolikar

Executive Vice President and Chief Commercial Officer
Michael P. Smith

Michael P. Smith

Executive Vice President, Chief Financial Officer, Treasurer and Secretary
Joanne Quan

Joanne Quan

Chief Medical Officer, Modis Therapeutics
Show more

Zogenix Office Locations

Zogenix has offices in Emeryville and Maidenhead
Emeryville, US (HQ)
5959 Horton St 5th Floor
Maidenhead, GB
West St
Show all (2)

Zogenix Financials and Metrics

Zogenix Revenue

Zogenix's revenue was reported to be $3.65 m in FY, 2019
USD

Net income (Q2, 2020)

(53.3m)

EBIT (Q2, 2020)

(71.5m)

Market capitalization (25-Sept-2020)

970.3m

Closing stock price (25-Sept-2020)

17.5

Cash (30-Jun-2020)

136.9m

EV

846.1m
Zogenix's current market capitalization is $970.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

37.6m44.3m33.0m40.5m27.2m28.9m9.8m3.6m

Revenue growth, %

23%(33%)6%

Cost of goods sold

19.3m19.5m21.2m15.8m10.7m

Gross profit

18.3m24.8m11.8m24.7m27.2m28.9m(908.0k)3.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.2m10.4m18.3m8.5m7.0m8.9m7.2m7.7m9.2m8.8m4.6m7.4m9.1m9.2m2.1m6.6m2.7m7.1m1.1m600.0k

Cost of goods sold

4.0m5.5m5.1m4.2m4.2m4.6m5.4m3.4m2.4m706.0k7.8m2.1m6.4m2.5m8.2m

Gross profit

6.3m4.9m13.3m4.2m2.8m4.3m1.8m4.3m6.8m8.1m4.6m7.4m9.1m1.4m27.0k179.0k209.0k(1.1m)

Gross profit Margin, %

61%47%72%50%40%48%25%56%74%92%100%100%100%15%1%3%8%(16%)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

56.5m41.2m72.0m42.2m155.3m91.6m293.5m68.5m62.1m

Accounts Receivable

4.9m5.6m6.7m8.9m1.4m1.4m

Prepaid Expenses

2.2m2.0m4.3m2.7m1.7m6.0m8.6m

Inventories

16.3m12.9m9.9m13.4m12.0m12.0m
USDQ2, 2011

Financial Leverage

-7.2 x
Show all financial metrics

Zogenix Acquisitions / Subsidiaries

Company NameDateDeal Size
Modis TherapeuticsAugust 26, 2019$250 m

Zogenix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Zogenix Online and Social Media Presence

Embed Graph

Zogenix News and Updates

Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Ru…

Zogenix Appoints Three Industry Leaders to Its Board of Directors

EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board …

Global DEE Market Insights, 2017-2028 - Eisai Pharmaceuticals (Fycompa; Perampanel), Zogenix (Fintepla; ZX008), Takeda/Ovid (Soticlestat; TAK-935/OV935), and Zynerba Pharma (Zygel; ZYN002)

DUBLIN, Feb. 10, 2020 /PRNewswire/ -- The "Developmental and Epileptic Encephalopathies (DEE) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the disease,...

The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome

FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo

Zogenix Completes Acquisition of Modis Therapeutics, Inc.

Acquisition strengthens Zogenix’s late-stage, rare disease pipeline with the addition of MT1621, a proprietary investigational therapy for Thymidine Kinase 2 deficiency (TK2d) Acquisition strengthens Zogenix’s late-stage, rare disease pipeline with the addition of MT1621, a proprietary investigation…

Zogenix Announces Acquisition of Modis Therapeutics, Inc.

EMERYVILLE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) --  Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company fo…
Show more

Zogenix Blogs

Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results

FDA PDUFA target action date of June 25, 2020 , for FINTEPLA® NDA in Dravet syndrome Plan to meet with FDA in second half of 2020 to discuss planned FINTEPLA Lennox-Gastaut syndrome sNDA Closed public offering of common stock for net proceeds of $221.7 million ; approximately $420 million in cash

Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5

Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5 Content Import Tue, 04/28/2020 - 08:02 Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5 04.28.20 This rel…

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Content Import Fri, 03/06/2020 - 16:05 Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option t…

Zogenix Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results Content Import Mon, 03/02/2020 - 16:01 Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results 03.02.20 This release is …

Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome

PDUFA target action date extended by three months to June 25, 2020 EMERYVILLE, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended
Show more

Zogenix Frequently Asked Questions

  • When was Zogenix founded?

    Zogenix was founded in 2006.

  • Who are Zogenix key executives?

    Zogenix's key executives are Stephen J. Farr, Gail M. Farfel and Bradley S. Galer.

  • How many employees does Zogenix have?

    Zogenix has 141 employees.

  • What is Zogenix revenue?

    Latest Zogenix annual revenue is $3.6 m.

  • What is Zogenix revenue per employee?

    Latest Zogenix revenue per employee is $25.9 k.

  • Who are Zogenix competitors?

    Competitors of Zogenix include Intarcia Therapeutics, Motif Bio and Circassia.

  • Where is Zogenix headquarters?

    Zogenix headquarters is located at 5959 Horton St 5th Floor, Emeryville.

  • Where are Zogenix offices?

    Zogenix has offices in Emeryville and Maidenhead.

  • How many offices does Zogenix have?

    Zogenix has 2 offices.